Two Decades of Experience in the Treatment of Paget’s Disease of Bone with Plicamycin (Mithramycin)

  • Will G. Ryan


Although Sir James Paget described the bone disease bearing his name in 1876, almost a century elapsed before effective therapies were developed. Now there are several and effective treatment of most if not all patients with the disorder will likely be possible within the next several years. Thus within the past 20 years, rapid strides have been made in our understanding of and ability to manage this disease.


Posttreatment Serum Urinary Hydroxyproline Anticipatory Nausea Rapid Stride Platelet Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ryan WG, Schwartz TB, Perlia CP: Effects of mithramycin on Paget’s disease of bone. Ann Intern Med 1969; 70: 549–557.PubMedGoogle Scholar
  2. 2.
    Kennedy BJ: Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med 1970; 49: 494–503.PubMedCrossRefGoogle Scholar
  3. 3.
    Monto RS, Talley RW, Caldwell MJ, et al: Observations on the mechanism of hemorrhagic toxicity in mithramycin therapy. Cancer Res 1969; 29: 697–704.PubMedGoogle Scholar
  4. 4.
    Kofman S, Eisenstein R: Mithramycin in the treatment of disseminated cancer. Cancer Chemother 1963; 32: 77.Google Scholar
  5. 5.
    Kofman S, Medrek TJ, Alexander RW: Mithramycin in treatment of embryonal cancer. Cancer 1964; 17: 938–948.PubMedCrossRefGoogle Scholar
  6. 6.
    Brown JH, Kennedy BJ: Mithramycin in the treatment of disseminated testicular neoplasms. N Engl J Med 1965; 272: 111–118.PubMedCrossRefGoogle Scholar
  7. 7.
    Ream NW, Perlia CP, Wolter J, Taylor SG III: Mithramycin therapy in disseminated germinal testicular cancer. JAMA 1968; 204: 1030–1036.PubMedCrossRefGoogle Scholar
  8. 8.
    Rebel A, Malkani K, Basle M: Particularités ultrastructurales des osteoclasts de la maladie de Paget. Rev Rhum Mal Osteo-Articulaires 1974; 41: 767–771.Google Scholar
  9. 9.
    Mills BG, Singer FR: Nuclear inclusions in Paget’s disease of bone. Science 1976; 194: 201–202.PubMedCrossRefGoogle Scholar
  10. 10.
    Eisenstein R, Passavoy M: Actinomycin D inhibits parathyroid hormone and vitamin D activity. Proc Soc Exp Biol Med 1964; 117: 77–79.PubMedGoogle Scholar
  11. 11.
    Rasmussen H, Arnaud C, Hawker C: Actinomycin D and response to parathyroid hormone. Science 1964; 154: 1019–1021.CrossRefGoogle Scholar
  12. 12.
    Fennelly JJ: Clinical and biochemical studies of Paget’s disease of bone with emphasis on the effects of RNA inhibitors actinomycin D and mithramycin. Ir J Med Sci 1971; 140: 431–448.PubMedCrossRefGoogle Scholar
  13. 13.
    Parsons V, Baum M, Self M: Effects of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease. Br Med J 1967; 1: 474–477.PubMedCrossRefGoogle Scholar
  14. 14.
    Perlia CP, Gubisch NJ, Wolter J, et al: Mithramycin treatment of hypercalcemia. Cancer 1970; 25: 389–394.PubMedCrossRefGoogle Scholar
  15. 15.
    Ryan WG, Schwartz TB, Northrop G: Experiences in the treatment of Paget’s disease of bone with mithramycin. JAMA 1970; 213: 1153–1157.PubMedCrossRefGoogle Scholar
  16. 16.
    Ryan WG, Schwartz TB, Northrop G: Treatment of Paget’s disease with mithramycin: Further experiences. Semin Drug Treat 1972; 2: 57–64.PubMedGoogle Scholar
  17. 17.
    Ryan WG: Treatment of Paget’s disease of bone with mithramycin. Clin Orthop 1977; 127: 106–110.PubMedGoogle Scholar
  18. 18.
    Condon JR, Reith SBM, Nassim JR, et al: Treatment of Paget’s disease of bone with mithramycin. Br Med J 1971; 1: 421–423.PubMedCrossRefGoogle Scholar
  19. 19.
    Elias EG, Evans JT: Mithramycin in the treatment of Paget’s disease of bone. J Bone Joint Surg 1972; 54: 1730–1736.PubMedGoogle Scholar
  20. 20.
    Aitken JM, Lindsey R: Mithramycin in Paget’s disease. Lancet 1973; 1: 1177.PubMedCrossRefGoogle Scholar
  21. 21.
    Eisinger JB, Recordier AM: Traitment de la maladie de Paget par la mithramycine. Lyon Med 1975; 11: 627–629.Google Scholar
  22. 22.
    Russell AS, Lentle BC: Mithramycin therapy in Paget’s disease. Can Med Assoc J 1974; 110: 397–400.PubMedGoogle Scholar
  23. 23.
    Russell AS, Chalmers IM, Percy JS, Lentle BC: Long term effectiveness of low dose mithramycin for Paget’s disease of bone. Arthritis Rheum 1979; 22: 215–218.PubMedCrossRefGoogle Scholar
  24. 24.
    Heath DA: The role of mithramycin in the management of Paget’s disease. Metab Bone Dis 1981,4,5:343–345.CrossRefGoogle Scholar
  25. 25.
    Condon JR, Surtees J, Robinson V: Control of osteitis deformans using glucagon, calcitonin and mithramycin. Postgrad Med J 1981; 57: 84–88.PubMedCrossRefGoogle Scholar
  26. 26.
    Hadjipavlou AG, Tsoukas GM, Siller TN, et al: Combination drug therapy in treatment of Paget’s disease of bone. J Bone Joint Surg 1977; 59; 1 (A): 1045–1051.PubMedGoogle Scholar
  27. 27.
    Pembrook RC, Chung CH, Carvallo AP: Effects of mithramycin and calcitonin in cardiovascular complications of Paget’s disease of bone. Conn Med 1975; 39: 209–214.PubMedGoogle Scholar
  28. 28.
    Theil GB, Ajlouni K: Mithramycin effects on calcium phosphorus and parathyroid hormone in osseous Paget’s disease. Am J Med Sci 1975; 269: 13–18.PubMedCrossRefGoogle Scholar
  29. 29.
    Ajlouni K, Theil GB: Effect of mithramycin on hydroxyproline metabolism in Paget’s disease. J Lab Clin Med 1977; 90: 803–808.PubMedGoogle Scholar
  30. 30.
    Ryan WG, Schwartz TB, Fordham EW: Mithramycin and long remission of Paget’s disease of bone. Ann Intern Med 1980; 92: 129.PubMedGoogle Scholar
  31. 31.
    Lebbin D, Ryan WG, Schwartz TB: Outpatient treatment of Paget’s disease of bone with mithramycin. Ann Intern Med 1974; 81: 635–637.PubMedGoogle Scholar
  32. 32.
    Ryan WG, Schwartz TB: Mithramycin treatment of Paget’s disease of bone: Exploration of combined mithramycin-EHDP therapy. Arthritis Rheum 1980; 23: 1155–1161.PubMedCrossRefGoogle Scholar
  33. 33.
    Ahn YS, Harrington WJ: Clinical uses of macrophage inhibitors. Adv Intern Med 1980; 25: 453–473.PubMedGoogle Scholar
  34. 34.
    Ahn YS, Harrington WJ, Mylvaganam R, et al: Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. Ann Intern Med 1984; 100: 192–196.PubMedGoogle Scholar
  35. 35.
    Owen M: The origin of bone cells in the postnatal organism. Arthritis Rheum 1980; 23: 1073–1077.PubMedCrossRefGoogle Scholar

Copyright information

© Elsevier Science Publishing Co., Inc. 1991

Authors and Affiliations

  • Will G. Ryan

There are no affiliations available

Personalised recommendations